Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
| 対象疾患 | Gastric Adenocarcinoma, GastroEsophageal Cancer |
|---|---|
| 相 | 第2相 |
| スポンサー | University of California, Irvine |
| ステータス | 完了 |
| 参加者数 | 34 名 |
| 介入（薬剤） | Cabozantinib, Pembrolizumab |
| 開始日 | 2020年2月4日 |
| 完了日 | 2023年11月25日 |
| 結果公開日 | 2025年8月11日 |
概要
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
Percentage of Participants With Progression-free Survival at 6 Months
| Cabozantinib and Pembrolizumab | 6 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Ad — Hoffmann-La Roche
- Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patient — National Cancer Institute (NCI)
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)
- Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Un — University of Southern California
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresecta — National Cancer Institute (NCI)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients — National Cancer Institute (NCI)